Pharmacy Utilization Meeting

August 5, 2022

**Attendees**

Linda Coyle (IMS) - absent  
Jennifer Stevens (IMS)  
David Angelaszek (IMS)  
Chuck May (IMS)  
Emily Carver (IMS)  
Kevin Ward (Georgia)  
Randi Rycroft (Idaho)  
Serban Negoita (NCI)  
Peggy Adamo (NCI) - absent  
Marina Matatova (NCI)  
Nadia Howlader (NCI) - absent

* It was mentioned at the July 22 meeting that it is questionable that patients that received only a single hormone treatment (defined as one of the first course therapy (FCOT) hormone treatments identified by Lois) should be counted as having received hormone therapy.
  + Patient may have been prescribed treatment but never picked up treatment, never took it or didn’t continue treatment.
* Randi suggested that such patients with any value of Rx Summ Hormone in the registry data should not have the augmented pharmacy version of this field set to 01.
* Jennifer, Emily and I worked on creating a dataset that the looked into cases. We focused the analysis on patients that had a single breast case in 2013-2019 and had linked pharmacy transactions.
* A patient was counted as having received a hormone treatment if they received a FCOT hormone drug within 12 months of diagnosis.
* We reviewed the results and made the following conclusions:
  + For patients that only had 1 FCOT hormone treatment in the first year –we should look into if subsequent FCOT hormone treatments were given outside the 1 year time window.
  + For patients that had only 1 FCOT hormone treatment with a date different than what is in the registry, we will take the better (earlier) date from the pharmacy transaction regardless if they had treatments past 1 year or not.
  + Patients that have only a single FCOT hormone treatment, regardless of timing, a registry value of Rx Summ Hormone = (00, 99) will translate to 88 in the corresponding augmented pharmacy field. However, Rx Summ Hormone values of 82-89 will translate to the same values in the augmented field.
    - **Action Item**: We will need clarification at the next meeting whether this should actually be a single FCOT hormone treatment in the first year and no subsequent FCOT hormone therapy after the first year. We will ask at next meeting on August 19, 2022.
  + Patients that have 1 FCOT hormone treatment in the first year after diagnosis and more past 1 year will have non-01 Rx Summ Hormone values set to 01 in the corresponding augmented pharmacy field. The same will be done for patients receiving multiple FCOT hormone treatments regardless of timing.
* Serban noted that he hopes Lois will have time to review the chemotherapy and immunotherapy lists Jennifer sent to her within the next two weeks.
  + Once that review is complete we can compute datasets for all augmented CTC fields.
* **Action item**: For patients that only had 1 FCOT hormone treatment in the first year –we should look into if subsequent FCOT hormone treatments were given outside the 1 year time window. Emily is working on this.
* **Action Item**:Work on computing the augmented CTC data items for the fields we can in the meantime. Jennifer and Emily are working on this.